Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 3 of the 21 sources its claims cite were checked for support.

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

Open access
McIntyre, Roger S., Lophaven, Søren, Olsen, Christina K. · 2014 · The International Journal of Neuropsychopharmacology

Abstract

The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression in adults with recurrent moderate-to-severe major depressive disorder (MDD) was evaluated. Patients (18-65 yr, N = 602) were randomized (1:1:1) to vortioxetine 10 or 20 mg/d or placebo for 8 wk in a double-blind multi-national study. Cognitive function was assessed with objective neuropsychological tests of executive function, processing speed, attention and learning and memory, and a subjective cognitive measure. The primary outcome measure was change from baseline to week 8 in a composite z-score comprising the Digit Symbol Substitution Test (DSST) and Rey Auditory Verbal Learning Test (RAVLT) scores. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). In the pre-defined primary efficacy analysis, both doses of vortioxetine were significantly better than placebo, with mean treatment differences vs. placebo of 0.36 (vortioxetine 10 mg, p < 0.0001) and 0.33 (vortioxetine 20 mg, p < 0.0001) on the composite cognition score. Significant improvement vs. placebo was observed for vortioxetine on most of the secondary objectives and subjective patient-reported cognitive measures. The differences to placebo in the MADRS total score at week 8 were -4.7 (10 mg: p < 0.0001) and -6.7 (20 mg: p < 0.0001). Path and subgroup analyses indicate that the beneficial effect of vortioxetine on cognition is largely a direct treatment effect. No safety concern emerged with vortioxetine. Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.

Overview

CoChat Summary

TL;DR

In adults with recurrent moderate-to-severe major depressive disorder, vortioxetine 10 and 20 mg/d for 8 weeks significantly improved a composite cognition z-score versus placebo, with effects largely independent of depressive symptom improvement. Both doses also improved most objective and subjective cognitive measures, with nausea and headache as common adverse events and no suicide-related safety signal.

Key findings

  • On the primary composite cognition z-score, mean treatment differences versus placebo at week 8 were 0.36 (95% CI 0.22–0.50, p < 0.0001) for vortioxetine 10 mg and 0.33 (95% CI 0.19–0.47, p < 0.0001) for vortioxetine 20 mg.
  • DSST significantly separated from placebo for both doses; RAVLT acquisition stopped testing because p > 0.025 for each dose, while RAVLT delayed recall had p < 0.025 for each dose. Other cognitive measures separated from placebo (p < 0.05) except CRT for vortioxetine 20 mg; standardized effect sizes where p < 0.05 ranged from 0.23 to 0.52.
  • MADRS total score differences versus placebo at week 8 were −4.7 (10 mg, p < 0.0001) and −6.7 (20 mg, p < 0.0001). Path analysis estimated direct effects on cognition of 64% and 48% for the composite z-score and 66% and 56% for DSST for 10 and 20 mg, respectively; cognitive improvement was also seen in non-responders and non-remitters.
  • TEAEs occurred in 38.3% (placebo), 46.2% (10 mg), and 52.7% (20 mg); nausea in 4.1%, 16.4%, and 20.8%, and headache in 7.1%, 8.2%, and 12.6%. No TEAEs related to suicide or self-harm were found; suicidal ideation proportions were 11%, 9.3%, and 13%.

Methods

  • Randomized, double-blind, fixed-dose, placebo-controlled, 8-week study at 79 psychiatric inpatient/outpatient settings in 12 countries from December 2011 to May 2013. Patients were 18–65 years old with recurrent MDD, a current major depressive episode ≥3 months, and MADRS total score ≥26 at screening and baseline; 602 were randomized 1:1:1, and the all-patients-treated set included 598.
  • Treatments were vortioxetine 10 mg/d, vortioxetine 20 mg/d (10 mg/d in week 1, then 20 mg/d weeks 2–8), or placebo. Cognitive function was assessed with DSST, RAVLT, Trail Making Test A/B, Stroop, simple reaction time, choice reaction time, and the patient-reported Perceived Deficits Questionnaire; depressive symptoms used MADRS and CGI scales.
  • Primary efficacy analysis was change from baseline to week 8 in a composite z-score weighting DSST 0.5 and RAVLT acquisition and delayed recall 0.25 each, analyzed in the full-analysis set using MMRM with treatment and center as fixed factors and baseline composite z-score as covariate.

Limitations

  • Stated by the authors: treatment duration was only 8 weeks; eligible patients may not be representative of adults with MDD seen in normal clinical practice; individuals with an index episode and/or milder baseline severity were excluded; results pertain only to the two doses evaluated.
  • Evident from the text: the composite z-score was used for the first time in this study and was based on post-hoc analysis of an elderly MDD study; some secondary analyses were not multiplicity-controlled and reported nominal p-values; no active comparator was included, so comparative efficacy versus other antidepressants is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s1461145714000546

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Standardized effect size (Cohen's d) for the neuropsychological tests (FAS, OC). DSST, Digit Symbol Substitution Test; FAS, full-analysis set; OC, observed cases; RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test, Stroop; SRT, simple reaction time task; CRT, choice reaction time task. *p < 0.05, **p < 0.01, ***p < 0.001 vs. placebo. p-values for TMT, Stroop, SRT and CRT are not corrected for multiplicity.
Fig. 1. Standardized effect size (Cohen's d) for the neuropsychological tests (FAS, OC). DSST, Digit Symbol Substitution Test; FAS, full-analysis set; OC, observed cases; RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test, Stroop; SRT, simple reaction time task; CRT, choice reaction time task. *p < 0.05, **p < 0.01, ***p < 0.001 vs. placebo. p-values for TMT, Stroop, SRT and CRT are not corrected for multiplicity.CC BY · PubMed Central
Fig. 2. Estimated Montgomery-Åsberg Depression Rating Scale (MADRS) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF, FAS, ANCOVA). The mean improvement from baseline to week 8 in the MADRS total score was −10.9 points (placebo), −15.6 points (vortioxetine 10 mg), and −17.6 points (vortioxetine 20 mg). ANCOVA, analysis of covariance; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model for repeated measures. Patient numbers at each visit are shown below the x-axis for each treatment group. **p < 0.01; ***p < 0.001 vs. placebo. p-values are not corrected for multiplicity.
Fig. 2. Estimated Montgomery-Åsberg Depression Rating Scale (MADRS) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF, FAS, ANCOVA). The mean improvement from baseline to week 8 in the MADRS total score was −10.9 points (placebo), −15.6 points (vortioxetine 10 mg), and −17.6 points (vortioxetine 20 mg). ANCOVA, analysis of covariance; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model for repeated measures. Patient numbers at each visit are shown below the x-axis for each treatment group. **p < 0.01; ***p < 0.001 vs. placebo. p-values are not corrected for multiplicity.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 0 Not valid · 12 Not checked · 60 Own results and interpretations

37 more claims

Create a free account to see all 74 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 23
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 42 references

Research works printed but not linked: 6

  1. 2012, Int J Psychiatry Clin Pract, 16, 47
  2. 2012, Eur Neuropsychopharmacol, 22, S243
  3. 2004, J Psychiatry Neurosci, 29, 417
  4. 2010, Psychiatry Res, 76, 183
  5. 2013, Acta Neuropsychiatrica, 25, 20
  6. 2013, Biol Psychiatry, 73, 213S

Cited by

See all 433

Metadata

Authors
McIntyre, R. S., Lophaven, S., & Olsen, C. K.
Affiliations
  • University Health Network (CA)
  • Lundbeck (Denmark) (DK)
Corresponding author
McIntyre, Roger S.
Venue
The International Journal of Neuropsychopharmacology
Published
2014-04-30
Volume
17
Issue
10
Pages
1557-1567
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2153644230
Cited by
433
References
42
Citations by year
2026: 17 · 2025: 24 · 2024: 33 · 2023: 34 · 2022: 32 · 2021: 39 · 2020: 28 · 2019: 35 · 2018: 31 · 2017: 38 · 2016: 45 · 2015: 64 · 2014: 13
FWCI
38.78
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Brain and Behavior Research Foundation
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Sunovion
  • H. Lundbeck A/S
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
vortioxetine, major depressive disorder, recurrent depression, cognitive function, executive function, processing speed, attention, learning and memory, subjective cognitive complaints, antidepressant efficacy, dose comparison
MeSH terms
Vortioxetine, Adolescent, Adult, Aged, Analysis of Variance, Cognition Disorders, Depression, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, International Cooperation, Male, Middle Aged, Neuropsychological Tests, Piperazines, Psychiatric Status Rating Scales, Sulfides, Anti-Anxiety Agents, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. https://app.cochat.ai/papers/10.1017/s1461145714000546
The paper
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014). A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145714000546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.